If there’s anything to be drawn from three recent Phase III failures—two in prostate cancer, one in stroke, all run by small biotechs—it’s that these days, you don’t believe the data. Trial design, concurrent therapies, patient selection, or even the conventional diagnostic indicator for the disease could be at fault.
Take the two prostate cancer snafus. Late in October, GPC Biotech AG’s orally administered platinum-based chemotherapeutic, satraplatin, failed to show...





